Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 540-546

  Poh, Say Bee ^a   Bai, Li Yuan ^a   Chen, Po Min ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Capecitabine; Chemotherapy; Gemcitabine; Hepatocellular carcinoma; Pegylated liposomal doxorubicin; Salvage

Indexed keywords

CAPECITABINE; DOXORUBICIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RASH; SALVAGE THERAPY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DOXORUBICIN; FATIGUE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIPOSOMES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM PROTEINS; PARESTHESIA; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 29044442874     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000177911.36579.3d     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Department of Health, Executive Yuan, Taiwan, ROC. Taiwan area main causes of death 2002. Table 10: main causes of death by cancer in Taiwan, 2002. Available at www.doh.gov.tw.
3. Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291-298.
4. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systemic review of randomized controlled trials. Ann Oncol. 1997;8:117-136.
5. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
6. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs. 1997;54(suppl 4):15-21.
7. Hong RL, Tseng YL, Chang FH. Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol. 2000;11:349-353.
8. Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol. 2000;11:113-114.
9. Miller RL, Bowen KE, Chun HG. A phase II study of liposomal doxorubicin (LD, Doxil) in patients with advanced hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC). Proc Am Soc Clin Oncol. 2002;21:2324a.
10. Valle JW, Dangoor A, Beech J, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer. 2005;92:628-630.
11. Schmidinger M, Wenzel C, Locker GJ, et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer. 2001;85:1850-1852.
12. Ruff P, Moodley SD, Rapoport DA, et al. Long-term follow-up of pegylated liposomal doxorubicin (Caelyx): a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol. 2001;20:667a.
13. Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2003;51:433-438.
14. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol. 2001;28:503-513.
15. Lai ECS, Choi TK, Cheng CH, et al. Doxorubicin for unresectable hepatocellular carcinoma. Cancer. 1988;62:1685-1687.
16. Di Maio M, De Maio E, Perrone F, et al. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002;35:S109-S114.
17. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gall-bladder carcinoma. Cancer. 2004;101:578-586.
18. Zhou J, Tang ZY, Fan J, et al. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial growth factor. Clin Cancer Res. 2003;9:6030-6037.
19. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanism of action. Semin Oncol. 1996;23:3-15.
20. Graziadei I, Kelly T, Schirmer M, et al. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′- difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol. 1998;28:504-509.
21. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89:750-756.
22. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002;94:3186-3191.
23. Guan Z, Wang Y, Maoleekoonpairqj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003;89:1865-1869.
24. Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology. 2001;60:313-315.
25. Yang TS, Wang CH, Hsieh RK, et al. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol. 2002;13:1771-1778.